Gilead Sciences, Inc. (NASDAQ:GILD) was the recipient of a significant drop in short interest in December. As of December 29th, there was short interest totalling 17,982,588 shares, a drop of 23.5% from the December 15th total of 23,511,423 shares. Based on an average daily volume of 6,470,028 shares, the days-to-cover ratio is currently 2.8 days. Approximately 1.4% of the company’s shares are sold short.

In other news, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the sale, the insider now directly owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 over the last three months. Insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Welch Investments LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $133,000. Horan Capital Advisors LLC. bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $144,000. Hanson & Doremus Investment Management increased its holdings in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $147,000. Hedge funds and other institutional investors own 75.94% of the company’s stock.

A number of analysts have recently commented on the company. Morgan Stanley reissued an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Bank of America cut their price objective on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 4th. Jefferies Group reaffirmed a “hold” rating and issued a $93.00 price objective on shares of Gilead Sciences in a research note on Wednesday, October 4th. Barclays reaffirmed an “overweight” rating and issued a $90.00 price objective on shares of Gilead Sciences in a research note on Wednesday, October 11th. Finally, Leerink Swann lifted their price objective on Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research note on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $85.03.

Shares of Gilead Sciences (GILD) opened at $79.02 on Friday. The firm has a market capitalization of $103,190.00, a P/E ratio of 8.99, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 earnings per share. equities analysts anticipate that Gilead Sciences will post 8.53 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio is 23.66%.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/13/gilead-sciences-inc-gild-short-interest-down-23-5-in-december.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.